Efficacy of pelvic floor muscle exercise or therapy with or without duloxetine: a systematic review and network Meta-analysis

Aging Male. 2022 Dec;25(1):145-155. doi: 10.1080/13685538.2022.2069238.

Abstract

Objectives: Postprostatectomy urinary incontinence (PPUI) is a serious complication despite surgical advances. Treatment options for PPUI include conservative care like Pelvic floor muscle exercise (PFME), which is a physiotherapy performed by the patients themselves; Pelvic floor muscle therapy (PFMT), a physiotherapy performed under the guidance of a therapist, and duloxetine treatment; and surgical interventions. In this study, network meta-analysis (NMA) was performed for direct comparison of these treatment options.

Materials and methods: The NMA pooled the odds ratios and 95% credible intervals using the number of patients achieving urinary continence and the total number of patients in an intention-to-treat population. The treatments were ranked based on the surface under the cumulative ranking curve (SUCRA) probabilities and the rankograms.

Results: The pooled overall ORs of patients achieving urinary continence compared with no treatment was 1.73 (95% CrI: 0.657, 4.71) in PFME, 2.62 (95% CrI: 0.553, 13.5) in PFME plus Duloxetine, and 4.05 (95% CrI: 1.70, 10.2) in PFMT. The SUCRA values of ranking probabilities for each treatment showed high rates of continence in the order of PFMT, PFME plus Duloxetine, and PFME.

Conclusion: The results suggest that patients with PPUI should undergo PFMT and consider duloxetine as an additional treatment option.

Keywords: Prostatectomy; duloxetine; pelvic floor; postoperative complications; urinary incontinence.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Duloxetine Hydrochloride / therapeutic use
  • Exercise Therapy / methods
  • Female
  • Humans
  • Male
  • Network Meta-Analysis
  • Pelvic Floor* / physiology
  • Treatment Outcome
  • Urinary Incontinence* / etiology
  • Urinary Incontinence* / therapy

Substances

  • Duloxetine Hydrochloride